Working... Menu

Patients Who Have Failed First Line Treatment for Locally Advanced and/or Metastatic Cervical Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00782041
Recruitment Status : Terminated (protocol violation)
First Posted : October 29, 2008
Last Update Posted : September 15, 2009
Information provided by:

Brief Summary:


  • To assess the overall response rate of oxaliplatin in patients with bidimensionally measurable disease at baseline.


  • To assess the safety and tolerability of oxaliplatin
  • To assess time to progression and overall survival.

Condition or disease Intervention/treatment Phase
Uterine Neoplasms Drug: Oxaliplatin Drug: 5-FluoroUracil Drug: Folinic acid Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 11 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Study of Oxaliplatin in Combination With 5-fluorouracil (5-FU) and Folinic Acid (FA) in Patients Who Have Failed First-line Treatment for Locally Advanced or Metastatic Cervical Cancer.
Study Start Date : January 2003
Actual Primary Completion Date : August 2003

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: 1
Oxaliplatin 85 mg/m² over 3 hours at Day 1 and Day 15. 5-FU 2,000 mg/m² over 4 hours at Day 1. Folinic acid 20 mg/m² Bolus at Day 1.
Drug: Oxaliplatin
85 mg/m²

Drug: 5-FluoroUracil
2,000 mg/m²

Drug: Folinic acid
20 mg/m²

Primary Outcome Measures :
  1. Response rate [ Time Frame: Throughout the study period ]

Secondary Outcome Measures :
  1. Progression-free survival [ Time Frame: Throughout the study period ]
  2. Overall survival [ Time Frame: Throughout the study period ]
  3. Adverse events [ Time Frame: Throughout the study period ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Have Locally advanced/metastatic squamous or adenocarcinoma of the cervix
  • Prior therapy with cisplatin allowed
  • First-line treatment may have been surgery,radiotherapy or chemotherapy either as a single agent or multi-modality therapy
  • Must have measurable disease
  • Histologically Proven Carcinoma of the cervix
  • ECOG PS ≤2
  • No other serious concomitant illness
  • Fully recovered from any prior therapy
  • Lab: ANC >1500 mm³, Platelets > 100000 mm³, Creatinine ≤ 1.5 x Normal value, Bilirubin ≤ 1.5 x Normal value, SGPT (ALT) ≤ 2.5 x Normal value

Exclusion Criteria:

  • Known allergy to one of the study drugs
  • Peripheral neuropathy > grade2

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00782041

Layout table for location information
Sanofi aventis administrative office
Bangkok, Thailand
Sponsors and Collaborators
Layout table for investigator information
Study Director: Paibulsirijit Sompob, MD Sanofi

Layout table for additonal information
Responsible Party: Medical Affairs Study Director, Sanofi-aventis Identifier: NCT00782041     History of Changes
Other Study ID Numbers: L_8311
First Posted: October 29, 2008    Key Record Dates
Last Update Posted: September 15, 2009
Last Verified: September 2009

Additional relevant MeSH terms:
Layout table for MeSH terms
Uterine Cervical Neoplasms
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Uterine Cervical Diseases
Uterine Diseases
Genital Diseases, Female
Folic Acid
Antineoplastic Agents
Molecular Mechanisms of Pharmacological Action
Antimetabolites, Antineoplastic
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Protective Agents
Vitamin B Complex
Growth Substances